- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06319313
Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer
March 18, 2024 updated by: Shanghai JMT-Bio Inc.
A Randomized, Controlled, Open-label Phase II/III Study of The Safety, Tolerability and Efficacy of JMT101 Combined With Docetaxel / HB1801 in Patients With sqNSCLC
This study is a phase II/III, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with docetaxel/ HB1801 in Patients with Squamous cell non-small cell lung cancer (sqNSCLC).
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
534
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Clinical Trials Information Group officer
- Phone Number: 86-0311-69085587
- Email: ctr-contact@cspc.cn
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ranged from 18 to 75 years old (inclusive), regardless of gender;
- Pathological diagnosis as sqNSCLC, with EGFR highly expressed, without other driver genes
- Tumor tissue available for central laboratory testing;
- Disease progression after prior anti PD-1/PD-L1 and platinum containing chemotherapy
- Measurable disease according to RECIST1.1;
- Eastern Cooperative Oncology Group (ECOG) score 0-1 points;
- Life expectancy ≥3 months
- Adequate main organs and bone marrow function.
- Patients must give informed consent to this study before the experiment and voluntarily sign a written informed consent form.
Exclusion Criteria:
- Previously used anti EGFR, or docetaxel;
- Central nervous system metastasis or meningeal metastasis;
- Patients with high risk of bleeding due to tumor invasion of important arteries;
- Uncontrolled or requiring repeated drainage of pleural effusion, pericardial effusion, or abdominal effusion;
- The adverse reactions of previous anti-tumor treatments (including radiotherapy) have not yet recovered to CTCAE 5.0 evaluation ≤ level 1 except for toxicity such as alocepia or fatigue, which is judged to be of no safety risk by researchers;
- Diagnosed as a second primary malignant tumor (except for skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder carcinoma, prostate carcinoma in situ, cervical carcinoma in situ and breast carcinoma in situ, etc.) within 5 years prior to the first administration of the study drug;
- Have received anti-tumor treatments such as systemic chemotherapy, biological therapy, immunotherapy, radical radiotherapy chemotherapy, etc. within 28 days before the first dose of the study drug;
- Have undergone major surgery (excluding needle biopsy) or suffered severe traumatic injury within 28 days before the first dose of study drug;
- Have received a live viral vaccine or live-attenuated vaccine within 28 days before the first dose of study drug or plan to receive it during the study;
- Have received palliative radiotherapy, small molecule targeted therapy, immunomodulatory drugs, NMPA approved modern traditional Chinese medicine preparations and other anti-tumor treatments, within 14 days before the first dose of study drug;
- Those who use strong CYP3A4 inducers within 14 days before the first administration of the study drug, or those who use strong CYP3A4 inhibitors within 1 week, or those who cannot suspend the use of the above drugs during the study;
- Have a history of serious cardiovascular disease;
- Have a history of serious lung disease;
- History of autoimmune diseases;
- History of immunodeficiency
- A history of gastrointestinal perforation and/or fistula within 6 months, or gastrointestinal obstruction and active inflammatory bowel disease within 28 days prior to the first study drug administration
- Have infectious diseases requiring systemic anti-infective treatment;
- Active hepatitis B; hepatitis C infection; syphilis infection, active tuberculosis;
- Known hypersensitivity or intolerance to any component of EGFR monoclonal antibody, human serum albumin, docetaxel, and its excipients; Individuals known to be allergic and/or contraindicated to glucocorticoids
- Women during lactation or pregnancy;
- Any male and female patients with fertility who refuse to use effective contraceptive methods throughout the entire trial period and within six months after the last administration;
- Other conditions that, in the opinion of the investigator, may affect the safety or compliance of drug treatment in this study, including but not limited to: psychiatric disorders, any severe or uncontrollable diseases, etc.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: JMT101+ docetaxel
|
JMT101, 6 mg/kg, IV infusion once every 2 weeks (one treatment cycle is 4 weeks).
or 9 mg/kg, IV infusion once every 3 weeks.
50 mg/m2, IV infusion once every 2 weeks (one treatment cycle is 4 weeks).
Or 75 mg/m2, IV infusion once every 3 weeks.
|
Experimental: JMT101+HB1801
|
JMT101, 6 mg/kg, IV infusion once every 2 weeks (one treatment cycle is 4 weeks).
or 9 mg/kg, IV infusion once every 3 weeks.
75 mg/m2, IV infusion once every 2 weeks (one treatment cycle is 4 weeks).
Or 100 mg/m2, IV infusion once every 3 weeks.
|
Experimental: HB1801
|
75 mg/m2, IV infusion once every 2 weeks (one treatment cycle is 4 weeks).
Or 100 mg/m2, IV infusion once every 3 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: Up to approximately 3 years
|
Up to approximately 3 years
|
|
Overall response rate (ORR)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Incidence and severity of adverse events (AE) and serious adverse events (SAE)
Time Frame: Up to approximately 3 years
|
Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0.
|
Up to approximately 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Control Rate (DCR)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Progression-free Survival (PFS)
Time Frame: Up to approximately 2 years
|
PFS, defined as the time from randomization to the first occurrence of disease progression as determined by the investigator with use of RECIST v1.1 or death from any cause, whichever occurs first.
|
Up to approximately 2 years
|
Duration of response(DOR)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
JMT101 Concentrations in Plasma
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Total and Free Docetaxel Concentrations in Plasma
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Li Zhang, M.D., Sun Yat-sen University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 1, 2024
Primary Completion (Estimated)
July 1, 2026
Study Completion (Estimated)
December 1, 2027
Study Registration Dates
First Submitted
March 13, 2024
First Submitted That Met QC Criteria
March 18, 2024
First Posted (Actual)
March 20, 2024
Study Record Updates
Last Update Posted (Actual)
March 20, 2024
Last Update Submitted That Met QC Criteria
March 18, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Docetaxel
Other Study ID Numbers
- JMT101-013
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Squamous Cell Non-small Cell Lung Cancer
-
Western Regional Medical CenterTerminatedNon-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer | Squamous Cell Non-Metastatic Non-Small Cell Lung CancerUnited States
-
Peking University First HospitalMerck Sharp & Dohme LLCNot yet recruitingAdvanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung CancerChina
-
AIO-Studien-gGmbHAstraZenecaTerminatedNSCLC | Non-squamous Non-small Cell Lung Cancer Stage II | Non-squamous Non-small Cell Lung Cancer Stage IIIA | Non-squamous Non-small Cell Lung Cancer Stage IIIB | Activating EGFR MutationGermany
-
National Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Unresectable Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic...United States
-
Bristol-Myers SquibbNo longer availableNon-squamous Non-Small Cell Lung Cancer | Squamous Non-Small Cell Lung CancerBrazil, Canada
-
Hoffmann-La RocheCompletedNon-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung CancerSpain, Italy, Poland, Brazil, Turkey, Serbia, France, Korea, Republic of, Romania, Hungary, Russian Federation, United States, United Kingdom, Germany, Greece, Japan, Thailand, Ukraine, China
-
National Cancer Institute (NCI)Active, not recruitingStage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...United States
-
European Organisation for Research and Treatment...WithdrawnSquamous Non-small Cell Lung Cancer | Non-Squamous Non-small Cell Lung Cancer
-
Eli Lilly and CompanyWithdrawnMetastatic Squamous Non-Small Cell Lung Cancer | Locally Advanced Squamous Non-Small Cell Lung CancerItaly, Romania, Germany, Belgium, Russian Federation, United States, United Kingdom
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of, United Kingdom
Clinical Trials on JMT101
-
Peking UniversityRecruitingEsophageal Squamous CarcinomaChina
-
Shanghai JMT-Bio Inc.CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingLocally Advanced or Metastatic Non-Small Cell Lung Cancer | EGFR Exon20 Insertion Mutations
-
Shanghai JMT-Bio Inc.Active, not recruitingLocal Advanced or Metastatic NSCLC | Harboring EGFR Common MutationChina
-
Shanghai JMT-Bio Inc.Not yet recruitingMetastatic Colorectal Cancer (mCRC)
-
Shanghai JMT-Bio Inc.CSPC ZhongQi Pharmaceutical Technology Co., Ltd.UnknownLocally Advanced or Metastatic Non-Small Cell Lung CancerChina
-
Shanghai JMT-Bio Inc.Not yet recruiting
-
Shanghai JMT-Bio Inc.CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Unknown